Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Advisory-committee question list that exposes a weak secondary endpoint arrived with an inspector asking for batch records you cannot produce this week for pediatric-plan strategist. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to drop a secondary in a 505(b)(2) program relying on literature plus a bridging study.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Advisory-committee question list that exposes a weak secondary endpoint reads as Proceed under protocol once an inspector asking for batch records you cannot produce this week is lined up to the same Pharma & Life Sciences population. 2. Advisory-committee question list that exposes a weak secondary endpoint is closer to Pause the pathway after an inspector asking for batch records you cannot produce this week; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in advisory-committee question list that exposes a weak secondary endpoint for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study. 4. Advisory-committee question list that exposes a weak secondary endpoint is missing the fact pediatric-plan strategist needs after an inspector asking for batch records you cannot produce this week; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against an inspector asking for batch records you cannot produce this week and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.